Sydney Jennings

Your daily dose of the clinical news you may have missed.

ACOG 2025: The Junonia study was designed to understand gaps in care for women with PPD using surveys of their clinicians and care coordinators.

ACOG 2025: Joy Baker, MD, discusses the importance of listening closely to how patients describe postpartum distress—and to read between the lines.

The nonhormonal neurokinin-3 receptor antagonist improved menopausal adiposity without appreciable impact on body weight or BMI, Santoro explained at 2025 ACOG meeting.

ACOG 2025: Pregnant patients may not want to discuss weight gain initially, so focus on overall perinatal health, and use that information to guide more conversation.

Your daily dose of the clinical news you may have missed.

LeThenia Joy Baker, MD, explains why PPD is often overlooked compared to physical pregnancy conditions like gestational diabetes.

ACOG 2025: Dr Baker shares how language can help create a trusting space for patients to speak openly about postpartum depression.

ACOG 2025: Joy Baker, MD, called for stronger cross-specialty collaboration to address maternal mental health after birth.

Steven Fleischman, MD, was inaugurated as ACOG’s 76th president, urging new fellows to lead with purpose and recognize their value in women’s health care.

Postmenopausal women taking fezolinetant experienced positive changes in body fat distribution, increases in which are known to increase risks of cardiometabolic disease.

Details on 12 key abstracts with clinical relevance for primary care, from menopause management to PPD screening and HPV testing.

The two areas where primary care physicians can contribute to improving women's health, according to Laurence Shields, MD.

Building trust with patients early on will help them feel comfortable discussing their symptoms and treatment preferences, says JoAnn Pinkerton, MD.

Your daily dose of the clinical news you may have missed.

A preview of sessions covering menopause and vasomotor symptoms during ACOG 2025 in Minneapolis, MN.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

Full results from the SURMOUNT-5 trial showed tirzepatide achieved 20.2% mean weight loss vs 13.7% with semaglutide in adults with obesity or overweight.

Your daily dose of the clinical news you may have missed.

An interview with Jeff Andrews, MD, FRCSC, of BD Life Sciences.

Your daily dose of the clinical news you may have missed.

An interview with Jeff Andrews, MD, FRCSC, of BD Life Sciences.

Your daily dose of the clinical news you may have missed.

PODCAST: Listen to our first episode for new research on bacterial vaginosis, a new treatment option for chronic urticaria, and more.

An interview with Jeff Andrews, MD, FRCSC, of BD Life Sciences.

Your daily dose of the clinical news you may have missed.

New data from UNITE study suggest fremanezumab was effective in alleviating migraine and comorbid MDD in patients with both conditions.